Why start with brain cancers?
These are notoriously difficult-to-treat cancers and often carry a devastating prognosis. The unmet need for patients with these cancers is dire.
The opportunity for Siren to help is massive.
Attempts to effectively treat brain cancers with systemic drugs have largely failed. Systemic drugs can’t cross the blood brain barrier and get to the tumor site. They are too toxic, and they are generally ineffective against these tumors.
The brain’s immune-privileged status allows us to locally deliver AAV without excluding patients based on neutralizing antibodies. AAV has already proven it can deliver transformative clinical results in the brain, underscoring its potential for treating brain tumors.
Our combination of AAV cytokine vectorization and direct tumor-targeting makes our approach ideally suited for brain cancers.
Introducing SRN-101, a universal AAV immuno-gene therapy drug product
Our first clinical program with SRN-101 will target high-grade gliomas, aggressive brain cancers with limited therapeutic options
Validated Payload
SRN-101 is a recombinant adeno-associated virus vector expressing an engineered cytokine payload with clinically validated immunomodulatory and antineoplastic effects
Regulatory Designations
The FDA has granted Orphan Drug and Rare Pediatric Disease Designations for SRN-101 for high-grade gliomas and pediatric-type diffuse high-grade gliomas, respectively
Leading the Way
High-grade gliomas are just the start; SRN-101’s promise extends to numerous solid tumor cancers
